Guggenheim Reiterates Buy on Summit Therapeutics, Maintains $40 Price Target

Guggenheim analyst Brad Canino reiterates Summit Therapeutics (NASDAQ:SMMT) with a Buy and maintains $40 price target.

byBenzinga Newsdesk

October 22, 2025

1 minute read

Guggenheim analyst Brad Canino reiterates Summit Therapeutics (NASDAQ:SMMT) with a Buy and maintains $40 price target.

M&A
News

Ericsson Received Approval from Committee on Foreign Investments in the United States to Acquire Vonage

By Charles Gross

Today, 4:15 PM

Ericsson (NASDAQ: ERIC) today announced that it has received clearance from the Committee on Foreign Investments in the United States (CFIUS) to complete its acquisition of Vonage Holdings Corp. (NASDAQ: VG) ("Vonage").

ERIC

Lattice Semiconductor’s Avant Ramps Likely To Drive Margins, Analysts Say Post 4Q

By Anusuya Lahiri

Today, 4:15 PM

Benchmark analyst David Williams maintained a Buy on Lattice Semiconductor Corp (NASDAQ:LSCC) and raised the price target from $65 to $95. LSCC’s…

LSCC

Volunteers Get Stoned To Help Police Understand Marijuana Impairment, Getting High To Further Education

By Nina Zdinjak

Today, 4:15 PM

A dozen medical marijuana patients in Maryland volunteered to help police officers understand what it looks like when someone is high.

CURLF

54 Biggest Movers From Yesterday

By Lisa Levin

Today, 4:15 PM

Gainers Longeveron Inc. (NASDAQ: LGVN) shares climbed 135.3% to close at $6.87 on Thursday. Longeveron said the FDA granted rare pediatric disease designation for the company’s Lomecel-B for the treatment of hypoplastic left heart syndrome.

AEHR

Guggenheim Reiterates Buy on Summit Therapeutics, Maintains $40 Price Target

Related Posts

Ericsson Received Approval from Committee on Foreign Investments in the United States to Acquire Vonage

Lattice Semiconductor’s Avant Ramps Likely To Drive Margins, Analysts Say Post 4Q

Volunteers Get Stoned To Help Police Understand Marijuana Impairment, Getting High To Further Education

54 Biggest Movers From Yesterday